Breast CancerNCT05561842
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
An observational study of Breast Cancer and Breast Cancer Female, run by Memorial Sloan Kettering Cancer Center at 8 sites in 2 countries.
Trial summary
The purpose of this study is to train Nigerian radiologists to perform ultrasound-guided breast biopsies. Researchers will use mHealth devices to create a sustainable and practical way of training radiologists in Nigeria to perform and clinically implement US-guided breast biopsies into their practice. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Cancer, Breast Cancer Female
- What is being tested?
- mHealth US-breast biopsy
- Type of treatment
- Surgery or procedure
- How many people
- 900 participants
- Where
- 8 sitesin 2 countries
- Study dates
- 21 Sep 2022to 21 Sep 2027
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Participants will be accrued in medical clinics as determined by the local investigators and local research staff. Informed consent forms approved by each local IRB will be obtained by research staff from each site.
Who may be able to join
- Age 18 and older female.
- Breast ultrasound demonstrating a solid mass that is suspicious for cancer, which would typically undergo either a blind biopsy or surgical excision at the Nigerian hospital where the patient is seeking diagnosis.
Who cannot join
- Participants unwilling to sign consent.
- Participants under the age of 18.
Trial locations and contacts
8 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
8 sites in 2 countries
Nigeria7 sites, 4 recruiting
- Recruiting
University Of Nigeria Teaching Hospital (UNTH) Ituku-Ozalla Enugu
Enugu
Nneka Iloanusi, MD, 08033143023, nneka.iloanusi@unn.edu.ng
- Active, not recruiting
University College Hospital (Data Collection Only)
Ibadan, Oyo State
- Recruiting
Lagos University Teaching Hospital
Idi-Araba, Lagos
Olubukola Omidiji, MD, 08122167403, olubukolaomidiji@yahoo.com
- Recruiting
Obafemi Awolowo University Teaching Hospitals Complex (Data Collection Only)
Ile-Ife
Adeleye Omisore, MD, +2348031538004, omisoreadeleye@yahoo.com
- Active, not recruiting
University of Ilorin Teaching Hospitals
Ilorin
- Recruiting
Federal Medical Centre Owo (Data Collection Only)
Owo, Ondo State
Adedeji Egberongbe, MD, 08034714382, deji_egbe@yahoo.com
- Active, not recruiting
Olabisis Onabanjo University Teaching Hospital (Data Collection Only)
Sagamu, Ogun State
United States1 site, 1 recruiting
- Recruiting
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065
Elizabeth Sutton, MD, 646-888-5455
About this study
Official title: Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria
The purpose of this study is to train Nigerian radiologists to perform ultrasound-guided breast biopsies. Researchers will use mHealth devices to create a sustainable and practical way of training radiologists in Nigeria to perform and clinically implement US-guided breast biopsies into their practice.
- Conditions
- Breast Cancer, Breast Cancer Female
- Being tested
- mHealth US-breast biopsy
- Keywords
- breast ultrasound, breast cancer, breast biopsy, breast cancer diagnosis, 21-325, Memorial Sloan Kettering Cancer Center
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
mHealth US-breast biopsyProcedure or surgery
During this study, women will undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.
| Study group | Role | What they receive |
|---|---|---|
| Participants with a solid mass on breast ultrasound | Participants will have a solid mass on breast ultrasound that is suspicious for breast cancer. Receives: Procedure: mHealth US-breast biopsy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of successful US-guided breast biopsy
Trainees will be evaluated using a passing criterion of 80% on a validated test that assesses competency based on the The Ottawa Surgical Competency Operating Room Evaluation (O-Score). There are 8 variables rated on a scale of 1-5. A trainee will be given a passing grade if the responses on all 8 variables are 4 or 5 and this is achieved in at least 80% of the unsupervised simulation and patient biopsies.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Sep 2022
- Study start21 Sep 2022
- Primary completion21 Sep 2027 (estimated)
- Study completion21 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by Memorial Sloan Kettering Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 900 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Eliabeth Sutton, MD, Principal investigator, Memorial Sloan Kettering Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05561842
- Sponsor's protocol ID
- 21-325
- Status last verified
- Oct 2026
- First submitted
- 27 Sep 2022
- Last updated
- 16 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.